Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Monte Rosa Therapeutics trailed consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, 2026, with revenue down 61.3% to about $9.0 million and adjusted EPS of -$0.43 versus the -$0.38 estimate (difference -$0.05, verdict: trailed). Revenue of $9.0 million also trailed the $12.9 million estimate (-31%, verdict: trailed) and was down from $23.2 million a year ago. With gross profit matching revenue at about $9.0 million, the quarter’s losses were driven below the gross line, as operating income came in at roughly -$49.1 million. Net income was -$43.4 million, down from -$12.3 million a year ago, while adjusted EPS declined from -$0.15 a year ago alongside the wider net loss. For the next period, consensus calls for EPS of -$0.36 on revenue of $18.9 million.
Next report — what to expect
Monte Rosa Therapeutics, Inc. (GLUE) reports on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.24 on revenue of $31.5 million. For trailing context, revenue fell -61.3% year over year last quarter. GLUE has beaten EPS in 5 of its 8 most recent quarters.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. develops precision medicines that harness the body's own protein-disposal machinery to eliminate therapeutically relevant targets as a NASDAQ-listed biotechnology company. In FY2025, it generated $123.7 million in revenue. The company was founded in 2019 and is based in Boston, Massachusetts.
Today's Snapshot
The day ended with GLUE 2.4% lower at 10.84, in line with a weaker sector. Shares changed hands at about half of its usual level.
Trading Volume
Below 10d avg (1.5M)
794.5K
vs S&P 500 Today
Underperforming Market
-1.91%
Updated: October 23, 2026 at 20:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$10.75 - $15.91Sell
- RSI (14)44.28Neutral
- Stochastic %K (14, 3, 3)66.83Neutral
- MACD Level (12, 26)-0.54Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.